COMBINATIONAL TCR-T CELL THERAPY TARGETING TUMOR ANTIGENS, TGF-BETA, AND IMMUNE CHECKPOINTS

摘要

The present disclosure is directed towards genetically engineered TCR-T cells to recognize tumor antigens and simultaneously secrete a binding protein that blocks an immune checkpoint molecule and TGF-beta. These engineered T cells demonstrate stronger antitumor response and reduced T cell exhaustion. The present disclosure provides immunotherapy against HPV- or EBV-positive cancers, among others.